Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 12,500 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 12,500 shares of Akero Therapeutics stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $53.49, for a total transaction of $668,625.00. Following the completion of the transaction, the insider now directly owns 169,721 shares in the company, valued at approximately $9,078,376.29. This trade represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Timothy Rolph also recently made the following trade(s):

• On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $55.04, for a total transaction of $1,376,000.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $43.43, for a total transaction of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $41.03, for a total transaction of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $35.88, for a total transaction of $224,250.00.

Akero Therapeutics Stock Performance

Shares of AKRO traded up $0.43 during midday trading on Monday, reaching $54.71. 2,271,173 shares of the stock were exchanged, compared to its average volume of 994,920. Akero Therapeutics, Inc. has a twelve month low of $21.02 and a twelve month high of $58.40. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The company has a market cap of $4.36 billion, a P/E ratio of -14.59 and a beta of -0.16. The stock’s 50 day simple moving average is $42.31 and its 200 day simple moving average is $39.64.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of ($1.01) by $1.91. On average, sell-side analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

AKRO has been the topic of a number of research analyst reports. Citigroup decreased their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright raised their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Finally, Bank of America raised their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a “buy” rating in a research note on Tuesday, May 27th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $82.50.

Hedge Funds Weigh In On Akero Therapeutics

A number of institutional investors have recently modified their holdings of the company. RTW Investments LP grew its holdings in Akero Therapeutics by 15.9% during the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock worth $190,840,000 after buying an additional 940,388 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Akero Therapeutics by 11.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company’s stock worth $194,997,000 after buying an additional 495,119 shares in the last quarter. Vanguard Group Inc. grew its holdings in Akero Therapeutics by 14.2% during the first quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company’s stock worth $171,256,000 after buying an additional 526,233 shares in the last quarter. Deep Track Capital LP grew its stake in Akero Therapeutics by 116.0% in the 4th quarter. Deep Track Capital LP now owns 1,490,000 shares of the company’s stock valued at $41,452,000 after purchasing an additional 800,216 shares during the period. Finally, SG Americas Securities LLC grew its stake in Akero Therapeutics by 93.3% in the 1st quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company’s stock valued at $46,786,000 after purchasing an additional 557,794 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.